Differential response of chronic plaque psoriasis to briakinumab vs. ustekinumab

Acta Derm Venereol. 2012 Jul;92(4):357-8. doi: 10.2340/00015555-1243.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Chronic Disease
  • Humans
  • Male
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Remission Induction
  • Treatment Outcome
  • Ustekinumab

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • briakinumab
  • Ustekinumab

Associated data

  • ClinicalTrials.gov/NCT00679731